| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/08/2001 | CA2314292A1 Topical cosmetic compositions comprising benzaldoximes |
| 01/08/2001 | CA2277537A1 Vegetarian dietary supplement drug |
| 01/06/2001 | CA2313339A1 Compositions containing fat-soluble substances in a carbohydrate matrix |
| 01/05/2001 | CA2314536A1 Stable microemulsions for the administration of fatty acids to humans or animals, and use of these microemulsions |
| 01/04/2001 | WO2001001140A1 Epitopes formed by non-covalent association of conjugates |
| 01/04/2001 | WO2001001131A1 Screening methods for compounds that affect melanogenesis |
| 01/04/2001 | WO2001000881A1 Antisense modulation of pi3k p85 expression |
| 01/04/2001 | WO2001000839A1 Tetanus toxin polypeptides |
| 01/04/2001 | WO2001000830A1 Sgip peptides |
| 01/04/2001 | WO2001000828A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | WO2001000824A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 01/04/2001 | WO2001000822A2 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 01/04/2001 | WO2001000821A1 Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof |
| 01/04/2001 | WO2001000808A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | WO2001000709A1 Copolymers for the transfer of nucleic acids to the cell |
| 01/04/2001 | WO2001000708A1 Combinations for introducing nucleic acids into cells |
| 01/04/2001 | WO2001000665A2 Inhibitors of memapsin 2 and use thereof |
| 01/04/2001 | WO2001000663A2 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | WO2001000658A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/04/2001 | WO2001000653A1 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 01/04/2001 | WO2001000652A2 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS |
| 01/04/2001 | WO2001000648A1 Stabilized viral envelope proteins and uses thereof |
| 01/04/2001 | WO2001000640A1 Macrolides |
| 01/04/2001 | WO2001000639A1 Novel sordarin derivative as a therapeutic antimicrobial agent |
| 01/04/2001 | WO2001000627A1 New indolocarbazole alkaloids from a marine actinomycete |
| 01/04/2001 | WO2001000626A1 Hexahydropyrrolo[1,2-c]pyrimidines as antiviral, antifungal and/or antitumor agents |
| 01/04/2001 | WO2001000622A1 Prodrugs of carbamate inhibitors of impdh |
| 01/04/2001 | WO2001000621A1 Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use |
| 01/04/2001 | WO2001000619A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 01/04/2001 | WO2001000618A1 Benzamide derivatives |
| 01/04/2001 | WO2001000617A2 Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same |
| 01/04/2001 | WO2001000616A1 Cholesterol biosynthesis inhibitors containing as the active ingredient aromatic compounds bearing cyclic amino groups |
| 01/04/2001 | WO2001000615A1 Respiratory syncytial virus replication inhibitors |
| 01/04/2001 | WO2001000612A2 Respiratory syncytial virus replication inhibitors |
| 01/04/2001 | WO2001000611A1 Respiratory syncytial virus replication inhibitors |
| 01/04/2001 | WO2001000610A1 Substituted benzimidazole |
| 01/04/2001 | WO2001000603A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/04/2001 | WO2001000594A1 Triazole compounds and combinatorial libraries thereof |
| 01/04/2001 | WO2001000589A1 6-carboxyphenyldihydropyridazinone derivatives and use thereof |
| 01/04/2001 | WO2001000587A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 01/04/2001 | WO2001000586A1 Compounds as selective agonists at alpha 2b or 2b/2c adrenergic receptors |
| 01/04/2001 | WO2001000585A1 Pyrazolidinol compounds |
| 01/04/2001 | WO2001000579A1 COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
| 01/04/2001 | WO2001000578A1 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof |
| 01/04/2001 | WO2001000573A1 Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same |
| 01/04/2001 | WO2001000570A1 Intermediates for the synthesis of benzimidazole compounds and process for the preparation thereof |
| 01/04/2001 | WO2001000566A2 Substituted phenoxyacetic acids |
| 01/04/2001 | WO2001000563A1 Amorphous nitric esters and their pharmaceutical compositions |
| 01/04/2001 | WO2001000558A1 Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates |
| 01/04/2001 | WO2001000554A2 Naphthoquinone derivatives and their use in the treatment and control of tuberculosis |
| 01/04/2001 | WO2001000251A1 Antiseptic and antimicrobial pharmaceutical preparation of feracrylum |
| 01/04/2001 | WO2001000246A2 Hydrogels derived from chitosan and poly(ethylene glycol) |
| 01/04/2001 | WO2001000245A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 01/04/2001 | WO2001000243A1 Pharmaceutical complex |
| 01/04/2001 | WO2001000242A2 Polycation-based bioconjugates |
| 01/04/2001 | WO2001000239A1 Combinations of dopamine receptor antagonists with dopamine agonists |
| 01/04/2001 | WO2001000238A1 TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
| 01/04/2001 | WO2001000229A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | WO2001000228A1 Method for preventing tumoral growth |
| 01/04/2001 | WO2001000226A1 Ophthalmic ointments for treating infective eye diseases |
| 01/04/2001 | WO2001000223A2 Multiple agent diabetes therapy |
| 01/04/2001 | WO2001000217A1 Medicinal compositions for preventing or treating diarrhea |
| 01/04/2001 | WO2001000215A1 Compositions for treating or preventing neurodegeneration and cognitive decline |
| 01/04/2001 | WO2001000214A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000213A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000212A1 Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies |
| 01/04/2001 | WO2001000211A1 A method for the treatment or prevention of coronary graft vasospasm |
| 01/04/2001 | WO2001000210A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | WO2001000209A1 Methods of use of fluoroquinolone compounds against bacteria |
| 01/04/2001 | WO2001000207A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000206A1 Vla-4 inhibitor compounds |
| 01/04/2001 | WO2001000205A1 Pharmaceutical composition containing sibutramine and orlistat |
| 01/04/2001 | WO2001000204A1 Method and pharmaceutical composition for parenteral administration of iron |
| 01/04/2001 | WO2001000203A1 Use of creatine or creatine compounds for skin preservation |
| 01/04/2001 | WO2001000202A1 Use of fluoxetine, paroxetine and other srsi as medicaments for increasing the capacity to refrain from consuming substances or having activities which create dependence |
| 01/04/2001 | WO2001000201A1 Curcumin and curcuminoid inhibition of angiogenesis |
| 01/04/2001 | WO2001000200A1 Injection-administered antiviral preparation |
| 01/04/2001 | WO2001000199A1 Compounds obtained from salvia species having antiviral activity |
| 01/04/2001 | WO2001000197A2 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 01/04/2001 | WO2001000196A2 Mirtazapine for weight gain in wasting diseases |
| 01/04/2001 | WO2001000195A2 Pharmaceutical compositions comprising nitric synthase inhibitors for treating decrease blood pressure |
| 01/04/2001 | WO2001000194A2 A method for optimizing immune activity in the treatment of auto-immune diseases and chronic immune conditions |
| 01/04/2001 | WO2001000193A2 Zinc ionophores as anti-apoptotic agents |
| 01/04/2001 | WO2001000192A2 Method of administering an imidazole derivative to obtain analgesia |
| 01/04/2001 | WO2001000191A2 Use of fosphenytion for the treatment of acute neuropathic pain |
| 01/04/2001 | WO2001000190A2 Hyaluronic acid derivatives for the prevention and treatment of cutaneous scars |
| 01/04/2001 | WO2001000188A2 Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and their use for preventing and/or treating anaemia |
| 01/04/2001 | WO2001000187A2 Pharmaceutical composition containing sibutramine and a lipase inhibitor |
| 01/04/2001 | WO2001000186A2 New use of 1,2,4-triazolo'1,5-a! pyrimidines |
| 01/04/2001 | WO2001000185A2 1,4-denzothiazepines to treat obesity related disorders |
| 01/04/2001 | WO2001000184A2 Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments |
| 01/04/2001 | WO2001000183A2 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 01/04/2001 | WO2001000181A2 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/04/2001 | WO2001000180A1 Self-emulsifying systems containing anticancer medicament |
| 01/04/2001 | WO2001000178A1 Tablets quickly disintegrating in mouth |
| 01/04/2001 | WO2001000177A1 Retard formulation of amoxicillin for oral administration |
| 01/04/2001 | WO2001000175A1 Mechanically stable pharmaceutical dosage forms, containing liquid or semi-solid surface-active substances |
| 01/04/2001 | WO2001000172A1 Cosmetic compositions |
| 01/04/2001 | WO2001000171A1 Cosmetic compositions |
| 01/04/2001 | WO2001000170A1 Cosmetic compositions |